FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W202933170> ?p ?o ?g. }

• W202933170 endingPage "107" @default.
• W202933170 startingPage "106" @default.
• W202933170 abstract "Injection of illicit drugs is a major health problem worldwide. There are currently an estimated 100,000 injection drug users in Canada (1). Infectious complications of injection drug use (IDU) include, but are not limited to, injection-related skin and soft tissue infection and abscesses, bloodstream infection and endocarditis, and infection by transmission of blood borne pathogens, such as HIV, hepatitis viruses and syphilis (2–4). In addition, IDU is associated with a general increased risk for infection such as with pneumonia and for acquisition of antimicrobial resistant organisms, most notably methicillin-resistant Staphylococcus aureus (5). Indirectly, IDU is associated with other behaviours and social circumstances that lead to further infectious disease risk and general adverse health consequences (6,7).Illicit drug use policy in Canada for the past century has been centred around criminalization and punishment of users and traffickers (8). However, there is increasing recognition of the outright failure of this approach. Illicit drug use remains common, and the market for illegal drug profits drives most of the organized crime activity in this country (9). Fueled in part by the apparent futility of criminalization and punishment approaches so far, there has been increasing recognition of the value of ‘harm reduction’ strategies. Harm reduction generally refers to programs, policies or interventions that aim to reduce or minimize the adverse consequences associated with drug use (10). Initial approaches surrounding harm reduction in the 1980s involving increased access to supplies of sterile needles and safe disposal or exchange led to reductions in infectious complications (11).In the 1990s, rates of HIV infection and deaths due to illegal drug use rose significantly in British Columbia, particularly in the downtown east side of Vancouver related to heroine abuse (12). Harm reduction was recognized as a necessary and major component of an intervention strategy and received growing community and governmental support. Insite (www.communityinsite.ca), a supervised injection facility, was subsequently opened as a pilot project following an exemption from the Controlled Drugs and Substances Act granted by the Government of Canada. Insite is located in the downtown east side of Vancouver (13). It provides IDUs with a supervised safe setting where sterile needles and syringes are supplied for the users to inject their own drugs. Health care personnel, including registered nurses, monitor patients and are available for management of adverse events. Hundreds of thousands of injections occur annually at this location.So what has been the impact of Insite? Use of the facility has been demonstrated to reduce needle sharing among its users (14). One analysis estimated that two to 12 deaths due to overdose have been averted annually by the facility (15). In another mathematical modelling study, it was estimated that Insite prevents an average of 35 cases of HIV infection and three deaths per year (16). In addition, these investigators found that after program costs were taken into account, Insite provided an estimated net societal benefit of $6,000,000 per year. Although other investigators have modelled infection rates and associated costs with varying results, the common conclusion is that infections and societal costs are reduced (17,18). It is noteworthy that Insite may also improve public order through less litter and disturbance resulting from public injection, increase the odds of users accessing addictions treatment and lead to earlier referral for treatment of infectious complications (19,20).Despite the fact that Insite has saved lives, prevented infections, promoted and facilitated addictions treatment, and saved public dollars, it has remained a source of controversy. Insite’s ability to remain open has been uncertain and is continually at risk with governmental challenges of the legality to continue operation (21). Opposition largely relates to objections to the ‘permissive’ use of controlled substances. In addition, a number of potential moral, ethical and political issues have been raised, including the use of tax payer funds to support this ultimately illegal activity, and unfounded concerns that such a facility may be condoning or legitimizing IDU. However, it is recognized that additional lives would be saved and infections prevented by the addition of supervised injecting facilities in many other Canadian cities (22).So what are our roles as members of the infectious disease and medical microbiology community in Canada? First, we believe that we must put aside any personal ethical and moral opposition that we may have against supervised injection facilities and focus on the fact that they can prevent infections, save lives and lessen the adverse societal impact of illicit drug use. Second, we should explicitly state our support to the public and political leaders not only for these centres, but for other novel initiatives that aim to reduce the adverse effects of illicit drug use and its associated infectious consequences. Finally, we must express our admiration, praise and gratitude to the individuals, communities and organizations in Canada that have championed the development of Insite and support further harm reduction initiatives for IDUs." @default.
• W202933170 created "2016-06-24" @default.
• W202933170 creator A5009747210 @default.
• W202933170 creator A5022055268 @default.
• W202933170 date "2012-01-01" @default.
• W202933170 modified "2023-09-27" @default.
• W202933170 title "Reducing the Adverse Impact of Injection Drug Use in Canada" @default.
• W202933170 cites W101731454 @default.
• W202933170 cites W1931184024 @default.
• W202933170 cites W1965846865 @default.
• W202933170 cites W1980089400 @default.
• W202933170 cites W1988778344 @default.
• W202933170 cites W1990978039 @default.
• W202933170 cites W1991088909 @default.
• W202933170 cites W1995201960 @default.
• W202933170 cites W2048537417 @default.
• W202933170 cites W2049473439 @default.
• W202933170 cites W2054096086 @default.
• W202933170 cites W2115034266 @default.
• W202933170 cites W2122273160 @default.
• W202933170 cites W2128657143 @default.
• W202933170 cites W2161959198 @default.
• W202933170 cites W2165639864 @default.
• W202933170 doi "https://doi.org/10.1155/2012/297530" @default.
• W202933170 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3476549" @default.
• W202933170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23997772" @default.
• W202933170 hasPublicationYear "2012" @default.
• W202933170 type Work @default.
• W202933170 sameAs 202933170 @default.
• W202933170 citedByCount "6" @default.
• W202933170 countsByYear W2029331702015 @default.
• W202933170 countsByYear W2029331702016 @default.
• W202933170 countsByYear W2029331702017 @default.
• W202933170 countsByYear W2029331702021 @default.
• W202933170 crossrefType "journal-article" @default.
• W202933170 hasAuthorship W202933170A5009747210 @default.
• W202933170 hasAuthorship W202933170A5022055268 @default.
• W202933170 hasBestOaLocation W2029331701 @default.
• W202933170 hasConcept C177713679 @default.
• W202933170 hasConcept C197934379 @default.
• W202933170 hasConcept C2780035454 @default.
• W202933170 hasConcept C2992293740 @default.
• W202933170 hasConcept C71924100 @default.
• W202933170 hasConcept C98274493 @default.
• W202933170 hasConceptScore W202933170C177713679 @default.
• W202933170 hasConceptScore W202933170C197934379 @default.
• W202933170 hasConceptScore W202933170C2780035454 @default.
• W202933170 hasConceptScore W202933170C2992293740 @default.
• W202933170 hasConceptScore W202933170C71924100 @default.
• W202933170 hasConceptScore W202933170C98274493 @default.
• W202933170 hasIssue "3" @default.
• W202933170 hasLocation W2029331701 @default.
• W202933170 hasLocation W2029331702 @default.
• W202933170 hasLocation W2029331703 @default.
• W202933170 hasLocation W2029331704 @default.
• W202933170 hasLocation W2029331705 @default.
• W202933170 hasLocation W2029331706 @default.
• W202933170 hasOpenAccess W202933170 @default.
• W202933170 hasPrimaryLocation W2029331701 @default.
• W202933170 hasRelatedWork W1966939585 @default.
• W202933170 hasRelatedWork W2025414842 @default.
• W202933170 hasRelatedWork W2092246656 @default.
• W202933170 hasRelatedWork W2374781999 @default.
• W202933170 hasRelatedWork W2426261983 @default.
• W202933170 hasRelatedWork W2527805684 @default.
• W202933170 hasRelatedWork W2885964272 @default.
• W202933170 hasRelatedWork W4236673861 @default.
• W202933170 hasRelatedWork W4252371801 @default.
• W202933170 hasRelatedWork W4298082289 @default.
• W202933170 hasVolume "23" @default.
• W202933170 isParatext "false" @default.
• W202933170 isRetracted "false" @default.
• W202933170 magId "202933170" @default.
• W202933170 workType "article" @default.